Drugs News and Research

RSS

Childhood brain cancer (ETMR/ETANTR): an interview with Dr. Nada Jabado, Department of Pediatrics at McGill University

Embryonal tumours with multilayered rosettes (ETMR) are rare, deadly brain tumours that affect mainly children below the age of 4 years. There are 300 cases reported but probably there are many more as this tumour is often misdiagnosed.

21 Jan 2014

HUB Foundation for Organoid Technology signs licensing agreement with STEMCELL Technologies

The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.

21 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.

21 Jan 2014

Par Pharmaceutical enters into definitive agreement to purchase JHP Group Holdings

Par Pharmaceutical Companies, Inc. today announced that it has entered into a definitive agreement to acquire JHP Group Holdings, the parent company of JHP Pharmaceuticals, a leading specialty pharmaceutical company that develops, manufactures and markets branded and generic sterile injectable products.

21 Jan 2014

Researchers find new candidate that may help combat malaria

Two of the most urgent challenges for scientists are the battles against food shortages and infectious diseases like malaria. Unfortunately, both the herbicides used to protect plants and the anti-infectives that shield us from disease rapidly lose their effectiveness as the target organisms develop resistance. In order to benefit both fields at once, scientists tested lead compounds from agrochemical research against infectious germs as well.

21 Jan 2014

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Gastroesophageal Reflux Disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.

20 Jan 2014

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

Rainbow Coral Corp. is well-positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology thanks to the innovative BiO Assay, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).

20 Jan 2014

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find-relatively quickly and cheaply-antibodies that have a desired effect on cells. The TSRI scientists used the technique to discover two antibodies that protect human cells from a cold virus.

20 Jan 2014

Queen's University Belfast scientists receive international recognition for research on microneedles

Scientists from Queen's University Belfast, whose research into microneedles is taking the pain out of injections, have received international recognition from one of the world's leading pharmaceutical science journals.

20 Jan 2014

Breakthrough technology could provide new approach for treatment of chronic wounds

A team of researchers led by an NIBIB grantee at Vanderbilt University has created a biodegradable scaffold that enables sustained, local delivery of gene-silencing factors called siRNA to promote tissue regeneration. The team recently used the scaffold to successfully deliver siRNA to mice in order to locally silence a gene normally responsible for inhibiting blood vessel formation.

20 Jan 2014

Studies aim to address urgent need to identify possible new methods for mesothelioma treatment

Mesothelioma is a very aggressive cancer associated with asbestos exposure, which is usually diagnosed in an advanced stage. So far no therapeutic strategy has proven effective against this deadly cancer and the prognosis remains very poor with only few exceptions.

20 Jan 2014

Scientists develop new class of molecules that provide new way to attack bacteria resistant to antibiotics

As concerns about bacterial resistance to antibiotics grow, researchers are racing to find new kinds of drugs to replace ones that are no longer effective. One promising new class of molecules called acyldepsipeptides - ADEPs - kills bacteria in a way that no marketed antibacterial drug does - by altering the pathway through which cells rid themselves of harmful proteins.

20 Jan 2014

Hospitals with more experience caring for patients with severe sepsis achieve better outcomes

A recent study led by Boston University School of Medicine (BUSM) shows that "practice may make perfect" when it comes to caring for patients with severe sepsis.

20 Jan 2014

Telestroke appears to be cost-effective for society

Researchers have found that using telemedicine to deliver stroke care, also known as telestroke, appears to be cost-effective for society. The research was recently published in the American Journal of Managed Care.

19 Jan 2014

Strontium should no longer be used for osteoporosis treatment, warns European Agency

All persons taking strontium supplements are warned that significant risks have been identified. Strontium drugs are not approved for treatment of osteoporosis in the United States. Now, the Risk Assessment Committee of the European Medicines Agency recommended that strontium should no longer be used to treat osteoporosis in Europe. The drugs Protelos/Osseor were specifically named as brand names for strontium ranelate.

19 Jan 2014

University of Huddersfield scientist awarded prestigious Clulow Award by British Pain Society

IN the UK alone, an estimated 7.8 million people have their lives blighted by chronic pain, and 44 per cent are failing to receive an accurate diagnosis and appropriate treatment. Now, a University of Huddersfield scientist, backed by funding from the British Pain Society and crucial support from the National Institute of Health Research, is embarking on research which aims to help doctors diagnose and treat one of the least understood but most widespread sources of chronic suffering.

18 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

Findings suggest possible clinical uses of ecstasy in treating anxiety and PTSD

Brain imaging experiments have revealed for the first time how ecstasy produces feelings of euphoria in users.

17 Jan 2014

FDA approves New Drug Application for PENNSA 2%

Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s).

17 Jan 2014

Drugs News and Research

Childhood brain cancer (ETMR/ETANTR): an interview with Dr. Nada Jabado, Department of Pediatrics at McGill University

HUB Foundation for Organoid Technology signs licensing agreement with STEMCELL Technologies

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

Par Pharmaceutical enters into definitive agreement to purchase JHP Group Holdings

Researchers find new candidate that may help combat malaria

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

RBCC's partner Nano3D Biosciences develops new 3D bioprinting system

TSRI scientists use new technique to discover two antibodies that protect human cells from cold virus

Queen's University Belfast scientists receive international recognition for research on microneedles

Breakthrough technology could provide new approach for treatment of chronic wounds

Studies aim to address urgent need to identify possible new methods for mesothelioma treatment

Scientists develop new class of molecules that provide new way to attack bacteria resistant to antibiotics

Hospitals with more experience caring for patients with severe sepsis achieve better outcomes

Telestroke appears to be cost-effective for society

Strontium should no longer be used for osteoporosis treatment, warns European Agency

University of Huddersfield scientist awarded prestigious Clulow Award by British Pain Society

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Findings suggest possible clinical uses of ecstasy in treating anxiety and PTSD

FDA approves New Drug Application for PENNSA 2%

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News